by | Jul 2, 2024 | Publications
Support Care Cancer. 2024 Jul 2;32(7):479. doi: 10.1007/s00520-024-08663-4. ABSTRACT PURPOSE: Continuous lenalidomide maintenance treatment after autologous stem cell transplantation delivers improvement in progression free and overall survival among newly diagnosed...
by | Jul 2, 2024 | Publications
Int J Hematol. 2024 Jul 2. doi: 10.1007/s12185-024-03812-1. Online ahead of print. ABSTRACT Basic research to expand treatment options for multiple myeloma is greatly needed due to the refractory nature of the disease. Histone deacetylase (HDAC) inhibitors, which are...
by | Jul 2, 2024 | Publications
J Exp Clin Cancer Res. 2024 Jul 1;43(1):183. doi: 10.1186/s13046-024-03110-y. ABSTRACT BACKGROUND: Leukocyte Ig-like receptor B family 4 (LILRB4) as an immune checkpoint on myeloid cells is a potential target for tumor therapy. Extensive osteolytic bone lesion is the...
by | Jul 2, 2024 | Publications
Br J Haematol. 2024 Jul 1. doi: 10.1111/bjh.19623. Online ahead of print. ABSTRACT This Good Practice Paper provides recommendations for the diagnosis and initial management of transplant-eligible high-risk myeloma patients. It describes recent updates to the genetic...
by | Jul 2, 2024 | Publications
Cureus. 2024 Jun 1;16(6):e61504. doi: 10.7759/cureus.61504. eCollection 2024 Jun. ABSTRACT BACKGROUND: Multiple myeloma (MM) immunophenotyping (IPT) and measurable residual disease (MRD) monitoring by flow cytometry is a surrogate for progression-free survival and...
by | Jul 2, 2024 | Publications
Zhonghua Xue Ye Xue Za Zhi. 2024 Apr 14;45(4):345-350. doi: 10.3760/cma.j.cn121090-20231203-00289. ABSTRACT Objective: This study investigated the efficacy and safety of denosumab (DENOS) versus zoledronic acid (ZOL) in the bone disease treatment of newly diagnosed...
